Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
REVENUES:
Revenue	$ 108,383	$ 152,400
OPERATING EXPENSES:
General and administrative expense, exclusive of depreciation expense shown below	8,461	19,567
Depreciation	4,633	5,042
Amortization	238	399
Impairments and other charges		122,204
Other (income) expense, net	(721)	(970)
OPERATING INCOME (LOSS)	11,622	(108,973)
Interest expense	1,363	3,411
Income (loss) from continuing operations before income tax expense	10,259	(112,384)
Income tax expense (benefit)	2,052	(4,046)
Income (loss) from continuing operations	8,207	(108,338)
Net income (loss)	8,207	(108,338)
Net income attributable to non-controlling interest	102	83
Net income (loss) attributable to Core Laboratories N.V.	$ 8,105	$ (108,421)
EARNINGS (LOSS) PER SHARE INFORMATION:
Basic earnings (loss) per share from continuing operations	$ 0.18	$ (2.44)
Basic earnings (loss) per share attributable to Core Laboratories N.V.	0.18	(2.44)
Diluted earnings (loss) per share from continuing operations	0.18	(2.44)
Diluted earnings (loss) per share attributable to Core Laboratories N.V.	$ 0.18	$ (2.44)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	45,177	44,447
Assuming Dilution (in shares)	45,964	44,447
Service [Member]
REVENUES:
Revenue	$ 83,982	$ 109,967
OPERATING EXPENSES:
Cost of product sales, exclusive of depreciation expense and impairment and other charges shown below	63,533	80,941
Product [Member]
REVENUES:
Revenue	24,401	42,433
OPERATING EXPENSES:
Cost of product sales, exclusive of depreciation expense and impairment and other charges shown below	$ 20,617	$ 34,190